Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Receives Average Recommendation of “Buy” from Analysts

Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFIGet Rating) have been given a consensus recommendation of “Buy” by the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $7.00.

INFI has been the subject of several research reports. B. Riley lowered their target price on Infinity Pharmaceuticals from $7.00 to $5.00 in a report on Monday, January 24th. Piper Sandler lowered their target price on Infinity Pharmaceuticals from $8.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, March 29th. Truist Financial lowered their target price on Infinity Pharmaceuticals from $12.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, March 31st. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, March 8th. Finally, StockNews.com assumed coverage on Infinity Pharmaceuticals in a research note on Thursday, March 31st. They set a “sell” rating for the company.

A number of large investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC acquired a new position in shares of Infinity Pharmaceuticals in the second quarter valued at about $31,000. Tradewinds Capital Management LLC acquired a new position in shares of Infinity Pharmaceuticals in the third quarter valued at about $34,000. Citigroup Inc. increased its holdings in shares of Infinity Pharmaceuticals by 141.7% in the third quarter. Citigroup Inc. now owns 10,073 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 5,906 shares during the period. Two Sigma Securities LLC purchased a new stake in shares of Infinity Pharmaceuticals in the third quarter worth about $39,000. Finally, Bank of America Corp DE boosted its stake in shares of Infinity Pharmaceuticals by 178.3% in the fourth quarter. Bank of America Corp DE now owns 23,595 shares of the biotechnology company’s stock worth $53,000 after buying an additional 15,117 shares during the last quarter. 53.07% of the stock is currently owned by institutional investors.

INFI opened at $0.83 on Tuesday. The business has a fifty day moving average of $1.05 and a 200 day moving average of $1.79. Infinity Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $3.89. The stock has a market cap of $74.27 million, a P/E ratio of -1.57 and a beta of 2.08.

Infinity Pharmaceuticals (NASDAQ:INFIGet Rating) last issued its earnings results on Tuesday, March 29th. The biotechnology company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. Infinity Pharmaceuticals had a negative return on equity of 122.91% and a negative net margin of 2,436.06%. During the same period in the previous year, the business posted ($0.17) earnings per share. Sell-side analysts anticipate that Infinity Pharmaceuticals will post -0.58 EPS for the current fiscal year.

Infinity Pharmaceuticals Company Profile (Get Rating)

Infinity Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors.

Recommended Stories

Analyst Recommendations for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.